肠道微生物在肝硬化及相关并发症中的研究进展

鲁冰洁; 赵亚红; 安泳潼; 叶冠; 孙明瑜

doi:10.3969/j.issn.1001-5256.2018.11.037

肠道微生物在肝硬化及相关并发症中的研究进展

DOI: 10.3969/j.issn.1001-5256.2018.11.037

1. 上海中医药大学附属曙光医院上海中医药大学肝病研究所肝肾疾病病证教育部重点实验室
2. 上海中医药大学
3. 上海医药集团股份有限公司

基金项目:

上海市科委专项项目(15DZ1900104)；国家中医药管理局第四批中医(基础)优才(2017);国家中医药管理局中医肝胆病重点学科、慢性肝病虚损重点研究室和上海市中医临床重点实验室资助；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1673
- HTML全文浏览量: 43
- PDF下载量: 449
- 被引次数: 0
出版历程
- 出版日期: 2018-11-20

Research advances in gut microbiota in liver cirrhosis and related complications

Research funding:

摘要

摘要: 肝硬化是由各种因素导致慢性肝损伤的终末期纤维化疾病。大量研究表明肠道微生物(GM)参与肝硬化及相关并发症,如门静脉高压、肝性脑病、自发性细菌性腹膜炎和肝细胞癌的发生发展。其中,肠道屏障和肝脏免疫功能受损、细菌移位更是在肝硬化疾病进程中起重要作用。总结了GM在肝硬化及相关并发症中的作用,以肠道微生物为治疗靶标的研究进展和存在的问题,以期为该病的临床诊治提供新思路。
- 肠杆菌科 /
- 肝硬化 /
- 并发症 /
- 综述
Abstract: Liver cirrhosis is an end-stage fibrotic disease of chronic liver injury induced by various factors. Many studies have shown that gut microbiota ( GM) are involved in the development and progression of liver cirrhosis and related complications, such as portal hypertension, hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatocellular carcinoma. In addition, impaired intestinal barrier, compromised liver immunity, and bacterial translocation play a critical role in the progression of liver cirrhosis. This article summarizes the role of GM in liver cirrhosis and related complications and research advances and problems in GM as a therapeutic target, in order to provide new thoughts for clinical diagnosis and treatment.
- enterobacteriaceae /
- liver cirrhosis /
- complication /
- review

HTML全文

参考文献(43)

[1]FUKUI H, SAITO H, UENO Y, et al.Evidence-based clinical practice guidelines for liver cirrhosis 2015[J].J Gastroenterol, 2016, 51 (7) :629-650.

[2]QIN J, LI R, RAES J, et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature, 2010, 464 (7285) :59-65.

[3]MIURA K, OHNISHI H.Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (23) :7381-7391.

[4]WIEST R, ALBILLOS A, TRAUNER M, et al.Targeting the gutliver axis in liver disease[J].J Hepatol, 2017, 67 (5) :1084-1103.

[5]TILG H, CANI PD, MAYER EA.Gut microbiome and liver diseases[J].Gut, 2016, 65 (12) :2035-2044.

[6]SCHNABL B, BRENNER DA.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology, 2014, 146 (6) :1513-1524.

[7]BAJAJ JS, BETRAPALLY NS, GILLEVET PM.Decompensated cirrhosis and microbiome interpretation[J].Nature, 2015, 525 (7569) :e1-e2.

[8]BAJAJ JS, HEUMAN DM, HYLEMON PB, et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol, 2014, 60 (5) :940-947.

[9]GARCIA-PAGAN JC, GRACIA-SANCHO J, BOSCH J.Functional aspects on the pathophysiology of portal hypertension in cirrhosis[J].JHepatol, 2012, 57 (2) :458-461.

[10]MOGHADAMRAD S, MCCOY KD, GEUKING MB, et al.Attenuated portal hypertension in germ-free mice:Function of bacterial flora on the development of mesenteric lymphatic and blood vessels[J].Hepatology, 2015, 61 (5) :1685-1695.

[11]QIN N, YANG F, LI A, et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature, 2014, 513 (7516) :59-64.

[12]QUEVRAIN E, MAUBERT MA, MICHON C, et al.Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease[J].Gut, 2016, 65 (3) :415-425.

[13]KANG DJ, BETRAPALLY NS, GHOSH SA, et al.Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice[J].Hepatology, 2016, 64 (4) :1232-1248.

[14]AHLUWALIA V, BETRAPALLY NS, HYLEMON PB, et al.Impaired gut-liver-brain axis in patients with cirrhosis[J].Sci Rep, 2016, 6:26800.

[15]BAJAJ JS, BETRAPALLY NS, HYLEMON PB, et al.Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J].Hepatology, 2015, 62 (4) :1260-1271.

[16]RIGGIO O, MANNAIONI G, RIDOLA L, et al.Peripheral and splanchnic indole and oxindole levels in cirrhotic patients:A study on the pathophysiology of hepatic encephalopathy[J].Am J Gastroenterol, 2010, 105 (6) :1374-1381.

[17]MONTAGNESE S, BIANCARDI A, SCHIFF S, et al.Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis[J].Hepatology, 2011, 53 (2) :558-566.

[18]HUANG R, NI JJ, GAO Y.The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (6) :1325-1328. (in Chinese) 黄蓉, 倪加加, 高毅.肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系[J].临床肝胆病杂志, 2018, 34 (6) :1325-1328.

[19]LOO TM, KAMACHI F, WATANABE Y, et al.Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity[J].Cancer Discov, 2017, 7 (5) :522-538.

[20]ZHOU LX, HAN T, LIU BW, et al.A preliminary analysis of composition and structure of intestinal microbiota in patients with liver cirrhosis or hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (9) :1740-1744. (in Chinese) 周冷潇, 韩涛, 刘保文, 等.肝硬化及肝细胞癌患者肠道微生态组成和结构的初步分析[J].临床肝胆病杂志, 2017, 33 (9) :1740-1744.

[21]HACKSTEIN CP, ASSMUS LM, WELZ M, et al.Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis[J].Gut, 2017, 66 (3) :507-518.

[22]CARNEVALE R, RAPARELLI V, NOCELLA C, et al.Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells.Implications for hypercoagulability in cirrhosis[J].J Hepatol, 2017, 67 (5) :950-956.

[23]MUNOZ L, JOSE BORRERO M, UBEDA M, et al.Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis[J].Hepatology, 2012, 56 (5) :1861-1869.

[24]STEIB CJ, HARTMANN AC, V HESLER C, et al.Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis[J].Lab Invest, 2010, 90 (7) :1024-1032.

[25]DOI H, IYER TK, CARPENTER E, et al.Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population[J].Hepatology, 2012, 55 (3) :709-719.

[26]LEVY M, THAISS CA, ZEEVI D, et al.Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NL-RP6 inflammasome signaling[J].Cell, 2015, 163 (6) :1428-1443.

[27]WIEST R, LAWSON M, GEUKING M.Pathological bacterial translocation in liver cirrhosis[J].J Hepatol, 2014, 60 (1) :197-209.

[28]BELLOT P, GARCIA-PAGAN JC, FRANCES R, et al.Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis[J].Hepatology, 2010, 52 (6) :2044-2052.

[29]TELTSCHIK Z, WIEST R, BEISNER J, et al.Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense[J].Hepatology, 2012, 55 (4) :1154-1163.

[30]RYAN KK, TREMAROLI V, CLEMMENSEN C, et al.FXR is a molecular target for the effects of vertical sleeve gastrectomy[J].Nature, 2014, 509 (7499) :183-188.

[31]JIANG C, XIE C, LI F, et al.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J].J Clin Invest, 2015, 125 (1) :386-402.

[32]ARAB JP, KARPEN SJ, DAWSON PA, et al.Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J].Hepatology, 2017, 65 (1) :350-362.

[33]PARSEUS A, SOMMER N, SOMMER F, et al.Microbiota-induced obesity requires farnesoid X receptor[J].Gut, 2017, 66 (3) :429-437.

[34]RIDLON JM, ALVES JM, HYLEMON PB, et al.Cirrhosis, bile acids and gut microbiota:Unraveling a complex relationship[J].Gut Microbes, 2013, 4 (5) :382-387.

[35]KALAMBOKIS GN, MOUZAKI A, RODI M, et al.Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J].Clin Gastroenterol Hepatol, 2012, 10 (7) :815-818.

[36]ZHU Q, ZOU L, JAGAVELU K, et al.Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice[J].JHepatol, 2012, 56 (4) :893-899.

[37]KANG SH, LEE YB, LEE JH, et al.Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J].Aliment Pharmacol Ther, 2017, 46 (9) :845-855.

[38]LIANG S, WEBB T, LI Z.Probiotic antigens stimulate hepatic natural killer T cells[J].Immunology, 2014, 141 (2) :203-210.

[39]LUNIA MK, SHARMA BC, SHARMA P, et al.Probiotics prevent hepatic encephalopathy in patients with cirrhosis:A randomized controlled trial[J].Clin Gastroenterol Hepatol, 2014, 12 (6) :1003-1008.e1.

[40]BAJAJ JS, GILLEVET PM, PATEL NR, et al.A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy[J].Metab Brain Dis, 2012, 27 (2) :205-215.

[41]TAUXE WM, HAYDEK JP, REBOLLEDO PA, et al.Fecal microbiota transplant for Clostridium difficile infection in older adults[J].Therap Adv Gastroenterol, 2016, 9 (3) :273-281.

[42]GARCIA-LEZANA T, RAURELL I, BRAVO M, et al.Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis[J].Hepatology, 2018, 67 (4) :1485-1498.

[43]VERBEKE L, FARRE R, TREBICKA J, et al.Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats[J].Hepatology, 2014, 59 (6) :2286-2298.

施引文献

资源附件(0)

访问统计